NYZ Stock Overview Provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Novacyt Historical stock prices Current Share Price €0.62 52 Week High €1.39 52 Week Low €0.47 Beta -1.84 1 Month Change 11.15% 3 Month Change -24.54% 1 Year Change -12.09% 3 Year Change -85.52% 5 Year Change 398.39% Change since IPO 17.71%
Recent News & Updates Novacyt S.A. Closure of IT-IS International Limited Oct 08
First half 2024 earnings released: UK£0.25 loss per share (vs UK£0.12 loss in 1H 2023) Sep 27
Novacyt S.A. Appoints John Brown Cbe as Chairman, Effective from 1 October 2024 Sep 26
New minor risk - Financial data availability Sep 16
Novacyt S.A. to Report First Half, 2024 Results on Sep 26, 2024 Sep 12
Novacyt S.A., Annual General Meeting, Jun 26, 2024 May 22 See more updates Novacyt S.A. Closure of IT-IS International Limited Oct 08
First half 2024 earnings released: UK£0.25 loss per share (vs UK£0.12 loss in 1H 2023) Sep 27
Novacyt S.A. Appoints John Brown Cbe as Chairman, Effective from 1 October 2024 Sep 26
New minor risk - Financial data availability Sep 16
Novacyt S.A. to Report First Half, 2024 Results on Sep 26, 2024 Sep 12
Novacyt S.A., Annual General Meeting, Jun 26, 2024 May 22
Novacyt S.A. to Report Fiscal Year 2023 Results on May 30, 2024 May 21
Less than half of directors are independent May 16
Novacyt S.A. Notes DHSC Application for Summary Judgment Dismissed May 01
New minor risk - Financial data availability Apr 15 Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024
First half 2023 earnings released: UK£0.12 loss per share (vs UK£0.071 loss in 1H 2022) Oct 02
New major risk - Revenue and earnings growth Sep 29
Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023 Sep 13
Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023 Jul 28
New major risk - Share price stability Jul 06
Novacyt S.A., Annual General Meeting, Jun 15, 2023 May 10
Full year 2022 earnings released: UK£0.31 loss per share (vs UK£0.14 loss in FY 2021) Apr 28
Now 23% undervalued after recent price drop Feb 08
Novacyt S.A. to Report Fiscal Year 2022 Results on Apr 24, 2023 Jan 26
Now 21% undervalued after recent price drop Dec 15 Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022 Novacyt Announces Step Down of David Allmond as Member of the Board
Novacyt Announces Approval of genesig® SARS-CoV-2 Winterplex® 3 Gene Assay Panel in the UK Under CTDA Legislation Oct 26
Now 24% undervalued after recent price drop Oct 12
First half 2022 earnings released: UK£0.07 loss per share (vs UK£0.18 loss in 1H 2021) Sep 30
Novacyt S.A. Provides Group Financial Guidance for the Third Quarter and Year-To-Date Ended September 2022 and Fourth Quarter of 2022 Sep 29 Novacyt S.A. to Report First Half, 2022 Results on Sep 29, 2022 Sep 15
Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays Aug 05
Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay Jul 28
Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK Jul 15
Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeypox Assay in Response to the Recent Outbreak of the Virus in Non-Endemic Countries Jun 29
Novacyt S.A., Annual General Meeting, Jun 21, 2022 May 13
Full year 2021 earnings released: UK£0.14 loss per share (vs UK£1.94 profit in FY 2020) Apr 29
Novacyt S.A. Provides Update on DHSC Dispute Apr 26
Novacyt Announces Approval of COVID-19 Test Under CTDA Legislation Apr 12
CEO & Director recently bought €121k worth of stock Mar 28
Novacyt S.A. Announces Approval of the First Direct-To-PCR Covid-19 Test in the UK Under CTDA Legislation Feb 17
Novacyt S.A. to Report Fiscal Year 2021 Results on Apr 25, 2022 Feb 02
Investor sentiment improved over the past week Dec 18
Investor sentiment deteriorated over the past week Dec 04
Investor sentiment improved over the past week Nov 18
Investor sentiment improved over the past week Oct 23
Investor sentiment improved over the past week Aug 20
Novacyt S.A. Reiterate Revenue Guidance for the Full Year Aug 19
Full year 2020 earnings released: EPS UK£1.94 (vs UK£0.072 loss in FY 2019) Jun 23
Novacyt S.A. Provides Sales Guidance for the Full Year 2021 Jun 22
Novacyt S.A. Announces the Launch of Two New Polymerase Chain Reaction Assays, Expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 Variant Detection Portfolios Jun 03
Novacyt S.A. Announces Launch of VersaLab™ Portable May 26
Investor sentiment deteriorated over the past week May 26
Novacyt S.A. Announces Inclusion of SNPsig SARS-CoV-2 PCR Genotyping Portfolio in the NHS England Framework and Expansion of SNPsig Product Range May 17
Investor sentiment improved over the past week Apr 27
Novacyt S.A. Provides Earnings Guidance for the Year 2021 Apr 11
Investor sentiment deteriorated over the past week Apr 10
New 90-day low: €7.80 Feb 25
Novacyt S.A. Announces Launch of PCR Genotyping Assay Portfolio to Detect Covid-19 Variants Feb 02
Investor sentiment deteriorated over the past week Jan 30
New 90-day high: €13.26 Jan 26
Investor sentiment improved over the past week Jan 15
Novacyt S.A. Announces Board Changes Jan 06
Novacyt S.A. Appoints James McCarthy as Chief Financial Officer Jan 05
Novacyt S.A. Announces the Development of Three Tests for New Strains of COVID-19 and Avian Influenza Dec 14
Market bids up stock over the past week Dec 09
Market bids up stock over the past week Nov 17
CEO & Director recently bought €558k worth of stock Nov 14
Market pulls back on stock over the past week Nov 10
Market bids up stock over the past week Nov 05
Market pulls back on stock over the past week Oct 31
Market bids up stock over the past week Oct 27
New 90-day high: €11.02 Oct 21
Market bids up stock over the past week Oct 21
Market bids up stock over the past week Oct 19
Novacyt S.A. (ENXTPA:ALNOV) acquired IT-IS International Ltd. for £12 million. Oct 16
Novacyt Signs a New Supply Contract with the UK Department of Health and Social Care Oct 04
New 90-day high: €6.18 Oct 02
Novacyt S.A. Announces Launch of COVID-19 Antibody Test Sep 30
New 90-day high: €3.96 Sep 17 Shareholder Returns NYZ DE Biotechs DE Market 7D -6.4% -2.5% -2.6% 1Y -12.1% -14.2% 7.1%
See full shareholder returns
Return vs Market: NYZ underperformed the German Market which returned 7.1% over the past year.
Price Volatility Is NYZ's price volatile compared to industry and market? NYZ volatility NYZ Average Weekly Movement 11.5% Biotechs Industry Average Movement 6.7% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: NYZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NYZ's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases.
Show more Novacyt S.A. Fundamentals Summary How do Novacyt's earnings and revenue compare to its market cap? NYZ fundamental statistics Market cap €43.31m Earnings (TTM ) -€45.02m Revenue (TTM ) €22.37m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NYZ income statement (TTM ) Revenue UK£18.56m Cost of Revenue UK£29.52m Gross Profit -UK£10.96m Other Expenses UK£26.40m Earnings -UK£37.36m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.53 Gross Margin -59.05% Net Profit Margin -201.27% Debt/Equity Ratio 0%
How did NYZ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 03:04 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Novacyt S.A. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mathieu Jasmin Arkeon Finance Johann Carrier Invest Securities Stefan Hamill Numis Securities Ltd.
Show 3 more analysts 
